Tauopathy is a pathological hallmark of many neurodegenerative diseases. It is characterized by abnormal aggregates of pathological phosphotau and somatodendritic redistribution. One suggested strategy for treating tauopathy is to stimulate autophagy, hence, getting rid of these pathological protein aggregates. One key controller of autophagy is mTOR. Since stimulation of mTOR leads to inhibition of autophagy, inhibitors of mTOR will cause stimulation of autophagy process. In this report, tauopathy was induced in mice using annonacin. Blocking of mTOR was achieved through stereotaxic injection of siRNA against mTOR. The behavioral and immunohistochemical evaluation revealed the development of tauopathy model as proven by deterioration of behavioral performance in open field test and significant tau aggregates in annonacin-treated mice. Blocking of mTOR revealed significant clearance of tau aggregates in the injected side; however, tau expression was not affected by mTOR blockage.
Introduction
Microtubule-associated protein tau (MAPT/Tau) is an important cytoskeletal protein that maintains the structure and several functions of neural cells. Pathologically, however, MAPT detaches from attached microtubules leading to destabilized neural cytoskeleton and disturbed neural transmission (Spillantini and Goedert 2013) . This condition of detached and somatodendritic redistribution of tau ending with neuronal death is named tauopathy (Ludolph et al. 2009 ). Tauopathy plays a key role in the pathogenesis of many neurodegenerative disorders with a wide spectrum of symptoms, including cognitive, behavioral, and motor impairments. With the available animal models of tauopathy, that recapitulates pathology in the form of ptau aggregates in frontal cortex in transgenic mice, it could be achievable to study different therapeutic strategies on these models (SantaCruz 2005) .
As a growth disorder, (i.e., a disease caused by overgrowth just like cancer), pathological protein aggregates in neurodegenerative disorders (e.g., tauopathy) would benefit from targeting autophagy (Klionsky and Emr 2000) . One determinant of autophagy is the mammalian target of rapamycin (mTOR), which is a 289 kDa serinethreonine kinase, that is, conserved through the evolution of mammalians so sharing it with other organisms (DiazTroya et al. 2008; Laplante and Sabatini 2012) .
mTOR-a negative regulator of autophagy-is associated with multiple proteins to form two structurally and functionally distinct complexes viz.: mTORC1 and mTORC2 (Betz and Hall 2013) . Normally, mTORC1 interacts with ULK1 complex with inhibiting its kinase activity. Upon inactivation of mTORC1, ULK1 dissociates from it, restoring its kinase activity and initiating autophagic cascade. The temporal cortex neurons of patients with dementia with Lewy bodies (DLB) showed increased expression of mTOR especially at neurons revealing alpha-synuclein aggregates (Laplante and Sabatini 2012) .
Stimulation of autophagy via mTOR inhibition is a widely studied modality for neuroprotection in neurodegenerative diseases (Cuervo et al. 2005) . Stimulation of autophagy by rapamycin ameliorates the pathological accumulation of protein aggregates in Parkinson disease, and this effect protects against rotenone-induced apoptosis of neurons (Li et al. 2005) . Recently, our group used dual mTORC1/C2 blocker as a successful strategy for treating fenazaquin-induced tauopathy in LUHMES cell line (Salama et al. 2017) . In the present report, we evaluated the efficacy of siRNA blocking of mTOR in annonacininduced tauopathy model in mice, which was proved, previously, to be an easy and low-cost animal model for such disease (Rottscholl et al. 2016 ).
Materials and Methods

Ethical Approval
The present work was approved by the Institutional Review Board of Mansoura Faculty of Medicine, Mansoura University, Mansoura, Egypt (IRB-MFM).
Twenty-four male c57bl/6 mice were purchased from the Medical Experimental Research Center (MERC), Mansoura University, Egypt. Animals were treated according to the Guide for the Care and Use of Laboratory Animals (National Research Council 2011).
Tauopathy Model
To induce tauopathy, mice consumed graviola juice (Dafruta, Recife, Brazil) which is an industrially produced Annona muricata L. fruit juice with a composition of soursop puree (50%), water with sodium metabisulfite, sodium benzoate, and citric acid (Rottscholl et al. 2016 ). The tauopathy model was validated through preliminary pilot study before getting into the main experiment. This work builds on our previous work group on role of environmental agents in developing tauopathy (Yamada et al. 2014; Höllerhage et al. 2015) .
Mice were treated randomly with water (control group) or graviola juice (tauopathy group). The juice was diluted to 1:4 with water and fresh solutions were prepared twice a week. In tauopathy group (n = 16), treatment with juice instead of water started at age of 8 weeks. On the other hand, control group (n = 8) received water throughout the study period. Treatment continued for 12 months, as described previously (Rottscholl et al. 2016) . During this period, animals were assessed neurobehaviorally every 3 months, i.e., four times since the beginning of the experiment until sacrifice (open field test with ANYmaze™ computerized software analysis). The animal model of tauopathy was verified by immunohistochemical tests against various tau antibodies after sacrifice (described later in relevant section).
Stereotaxis Injection of siRNA
After verification-behaviorally-of tauopathy development in animals (12 months of annonacin treatment), siRNA mTOR (MyBiosource™, Catalog #MBS827329) was prepared in sterile DEPC water (Thermofisher™) (as recommended by manufacturer). Mice were anesthetized by intraperitoneal (IP) injection of 0.2% ketamine/xylazine mixture then positioned into a stereotactic frame (Stoelting Co. USA).
The intracerebral injections were performed with a Hamilton syringe (Stoelting™) according to the following coordinates from bregma: AP, − 0.18 cm; ML, + 0.15 cm; DV, − 0.18 cm (Franklin and Paxinos 1997) . The coordinates were chosen following previous works addressing specific intracerebral treatment options for tauopathy (Xu et al. 2014) . Two microliters of siRNAs solution containing 250 nM siRNA concentrations were injected at a rate of 0.2 μL/min. In mTOR siRNA-treated mice (n = 8), the right cerebral cortices were injected with siRNA targeting mTOR. In control mice (n = 8), animals were injected with 0.4 nmol of the sterile DEPC water.
Two weeks after siRNA injection, half of each mice group was perfused with 10 mM phosphate-buffered saline (PBS), followed by 150 mL of a cold fixative. After perfusion, the brains were post-fixed for 2 days with PFA then transferred to 15% sucrose solution in 100 mM PB containing 0.1% sodium azide stored at 4°C. The other half of mice were sacrificed with decapitation and brains were frozen at − 20°C for 1 month before using for semiquantitative/quantitative PCR.
Semi-Quantitative Reverse Transcription-PCR (RT-PCR)
Total mRNA was extracted by the RNA extraction kit (Promega Corporation, Madison, USA). RT-PCR of mTOR (forward: 5′-GCTCCAAAGACACCACCCA-3′; reverse: 5′-CACTCTCACTGTTGCTGCC-3′) and for MAPT (forward: 5′-TGGGGTTTAGGTCAGTGG-3′; reverse: 5′-GCTG TAGCCGCTGCGATC-3′). The following cycles were used: 94°C/3 min; 1, 94°C/30 s; 35, 58°C/30 s; 35, 72°C/45 s; 35.
Mouse Gapdh was taken as an internal control (forward: AGGCCGGTGCTGAGTATGTC; backward: TGCCTGCT TCACCACCTTCT).
Quantitative PCR (qPCR)
The qPCR was performed on Step one Plus™ real-time PCR system (Life Technologies, USA) using the comparative threshold cycle (Ct) method. mRNAs concentrations were assessed by the NanoDrop 2000 (Thermo Fisher Scientific, USA) and 1 μg of total mRNA from each sample was reversely transcripted into total cDNA by the Thermo Scientific™ RevertAid™ First Strand cDNA Synthesis Kit (Thermo Fisher Scientific, USA).
Immunohistochemistry
Brain tissues were stained using the following primary antibodies: AT8 antibody against pS202/pT205 tau, mouse AT 180 monoclonal phospho-PHF-tau pThr231 antibody (both from Thermo Scientific, Rockford, IL, USA; used 1:100) and AD2 antibody against pS396/ pS404 (BioRad, Hercules, CA; 1:1000), anti NeuN for neurons (Millipore, 1:1000), and anti-ionized calcium binding adaptor molecule 1 (Iba-1) (Wako Chemicals, Germany, 1:200) followed by biotinylated secondary antibodies for 10 min then the avidin-biotin-peroxidase complex (ABC). All the sections were washed several times with PBS between each incubation and labeling was then revealed by diaminobenzidine (DAB) which was used as a chromogen. Slides were counterstained with Meyer's hematoxylin, dehydrated, and cover slipped. Tissues were, then, examined under a light microscope (CX31RTSF; Olympus, Tokyo, Japan).
The number of phospho-tau positive neurons (AT8, AT180, and AD), NeuN positive cells, and Iba1positive cells were estimated, sections were assessed as each 10th section (thickness 20 μm). Frontal cortex coordinates were identified as described by Paxinos and Franklin Atlas, between 1.94 and 0.86 mm anterior and 0 to 2.0 mm lateral from the bregma.
Statistical Analysis
Data were expressed as mean + SD. Data analysis was performed, using Statistical Package for Social Science (SPSS 20, Chicago, USA), comparison of continuous variables was done using one-way ANOVA followed by post hoc analysis. 
Results
Behavioral Assessment Regular consumption of annonacin led to a progressive deterioration in neurobehavioral performance of mice in open field test. This was observed in path efficiency, rotation, freezing episodes, and maximum speed (Fig. 1) .
Quantitative PCR (qPCR) siRNA mTOR efficacy was assessed initially through decreasing mTOR expression in cell line before in vivo experiment. Two weeks after injection of siRNA mTOR, led to significant decrease in mTOR expression in the injected side (right frontal cortex) compared to controls (75%) (Fig. 2) . MAPT expression was significantly increased in annonacin-treated mice compared to controls (50%). On the other hand, mTOR silencing did not affect MAPT expression in the injected compared to the contralateral side.
Immunohistochemistry NeuN and Iba-1 staining revealed the absence of neuronal loss or inflammatory changes following stereotaxis needle injection in the cerebral cortex. Tauopathy model was verified by the tau aggregates in the frontal cerebral cortex in mice treated for 12 months with graviola juice (annonacin) as compared to controls. The NeuN staining, however, revealed no neuronal loss in hippocampus or cortex of tauopathy mice revealing that the model resembles early onset disease (Fig. 2) .
Discussion
Tauopathies are heterogeneous neurodegenerative diseases that are morphologically, biochemically, and clinically defined by the accumulation of abnormal tau proteins in the brain. The current report discussed the pivotal role of blocking mTOR in tauopathy mice model. Tau-directed therapies might be useful to slow down the progression of tauopathies including PD and AD. The current model was developed through daily treatment of c57bl/6 mice with annonacin for 1 year. This course of treatment led to significant aggregation of pathological tau in different brain areas without neuronal loss in the hippocampus. This represents an early stage of tauopathy as described previously (Rottscholl et al. 2016 ). Blocking of mTOR through injecting a siRNA sequence in right hemispheres using stereotaxis led to clearance of tau aggregates. On the other hand, it did not alter the level of mRNA tau denoting that inhibition of mTOR did not affect tau expression or synthesis. Several previous reports showed successful use of mTOR inhibition as a therapeutic strategy in neurodegenerative diseases through manipulating autophagy, hence, eradication of pathological protein aggregates, which is considered the pathological hallmarks in these disorders (Ozcelik et al. 2013; Jiang et al. 2014; Siman et al. 2015) . On the other hand, fewer reports showed contradictory findings through the absence of beneficial effects of mTOR manipulation in other mouse models including ALS (Zhang et al. 2011 ) and neuropathy (Nicks et al. 2014) . These different effects of mTOR manipulation indicate that useful effects of mTOR inhibition may be dependent on neurodegenerative pathogenesis.
Our previous work showed that complete blockage of mTOR through using dual mTORC1/C2 blocker offered significant therapeutic effects on an in vitro cellular model of tauopathy (Salama et al. 2017 ). The present report is consistent with these previous data. The variable reactions to target mTOR in different research may be related to different possible explanations: First, mTOR signaling is a major intracellular pathway with multiple downstream effects, thus, manipulation of mTOR may initiate various cascades and not only autophagy (Caccamo et al. 2014) . Second, most of earlier reports evaluated rapamycin or one of its rapalogues. It is known now that rapalogues affect mainly mTORC1 complex with minimal effects-in therapeutic doses-on mTORC2. The role of mTORC2, however, showed relevance to tauopathy as it controls phosphorylation and redistribution of tau (Tang et al. 2013 ). Moreover, mTORC2 seems to play an important role in counteracting cellular quiescence, hence, retarding aging process (Sousa-Victor et al. 2015) . Finally, it is not exactly known how overactive mTOR may initiate apoptotic pathway, but one proposed mechanism stems from the findings that mTOR is a potent inhibitor of autophagy and inhibition of mTOR may result in excessive induction of autophagy of cellular organisms including mitochondria (mitophagy) initiating apoptotic pathway (Laplante and Sabatini 2012) . Hence, uncontrolled inhibition of mTOR for a prolonged period is not advantageous approach in neurodegenerative disorders. We used siRNA blocking of mTOR as it represents a validated, easy, and cost-effective method to study localized blocking of genes in animal models (Xu et al. 2014 ).
An important point to show in this report is that tau synthesis was not affected by mTOR manipulation as evidenced by PCR results, as previously reported (Siman et al. 2015) ; however, stimulation of autophagy was useful in clearing the aggregated tau, since it has been shown that mTOR controls distribution and relocalization of tau rather than synthesis (Tang et al. 2013) . We believe that these results could be of importance if reflected on drug discovery for treatment of tauopathy. Guided that tauopathy plays pivotal role in many neurodegenerative diseases; the present early findings could be applied in different tauopathy-related disorders.
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